Differences

This shows you the differences between two versions of the page.

--- home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq
+++ home:starting:physician:reluctant [04.26.2019] – [Specific research] sallieq
@@ Line 185: / Line 185: @@
 {{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&300|4 hourly compared to 6 hourly dosing}}
+The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) PMID 16508590
 short extract for each research study follows:
-The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}}))
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:88888888}}))
-Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}})) Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}}))
+Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}})) PMID 24772521
-) Alzheimer's disease and dementia1 (({{pubmed>long:20068258}}))
-prevent migraines (({{pubmed>long:12503978}}))
-inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}}))
+Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:20074257}}))  PMID 20074257
-mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:23775504}}))
-protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}}))
+Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450
-reduce liver fibrosis (({{pubmed>long:19303015}}))
-treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}}))
+Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}}))  PMID 26138656
-inflammation in myocarditis (({{pubmed>long:16336207}}))
+)
-C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}}))
-cytokine damage (({{pubmed>long:88888888}}))
+Alzheimer's disease and dementia1 (({{pubmed>long:20068258}}))  PMID 20068258
+prevent migraines (({{pubmed>long:12503978}}))  PMID 12503978
+inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}}))  PMID 12871826
+mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:88888888}} ))
+protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}}))  PMID 12709417
+reduce liver fibrosis (({{pubmed>long:19303015}}))  PMID 19303015
+treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}}))  PMID 15837532
+inflammation in myocarditis (({{pubmed>long:16336207}}))  PMID 16336207
+C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}}))  PMID 16939632
+cytokine damage (({{pubmed>long:88888888}}))  PMID
+in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}}))  PMID 23511341
+renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))  PMID 23511341
+olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}}))   PMID 24842388
+* treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))  PMID 25363367
+* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))  PMID 25904217
+* decreases viability of malignant cell lines(({{pubmed>long:28666209}}))  PMID 28666209
+* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}}))  PMID 19124398
+* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))  PMID 25891757
+* improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}}))  PMID 23303198
+* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
+* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}}))  PMID 22418908
+Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})),   PMID 25363367
+olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})),   PMID 25904217
+decreases viability of malignant cell lines (({{pubmed>long:28666209}})),   PMID 28666209
+carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced
+the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),  PMID 19124398
-in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}}))
+improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),  PMID 25891757
-renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))
-olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}}))
+improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),  PMID 23303198
-* treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))
+OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
-* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))
-* decreases viability of malignant cell lines(({{pubmed>long:28666209}}))
-* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}}))
-* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))
-* improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}}))
-* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
-* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}}))
-Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})),
-olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})),
-decreases viability of malignant cell lines (({{pubmed>long:28666209}})),
-carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),
-improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),
-improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),
-OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
-Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))
+Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))   PMID 25001274

home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1